<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523428</url>
  </required_header>
  <id_info>
    <org_study_id>HO159</org_study_id>
    <nct_id>NCT04523428</nct_id>
  </id_info>
  <brief_title>REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)</brief_title>
  <official_title>A Prospective, Multicenter, Phase-II Trial of Venetoclax Plus Acalabrutinib in Patients Who Have Relapsed After First Line Venetoclax + Anti-CD20 mAb Treatment for Chronic Lymphocytic Leukemia (CLL or SLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stichting Hemato-Oncologie voor Volwassenen Nederland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are&#xD;
      expected to soon become standard practice in first-line patients with chronic lymfocytic&#xD;
      leukemia (CLL). The advantage of a fixed duration venetoclax combination as part of&#xD;
      first-line treatment is the potential to retreat with venetoclax in patients who develop&#xD;
      relapsed disease after a treatment free period. However, efficacy of venetoclax retreatment&#xD;
      following a fixed duration venetoclax combination is still hypothetical as clinical data are&#xD;
      lacking. Thus, there is an urgent need for data proving efficacy of venetoclax combinations&#xD;
      following venetoclax treatment cessation. Testing of a novel venetoclax-containing regimen&#xD;
      for relapsed CLL without the repeat of anti-CD20 monoclonal antibody (mAb) is a rational&#xD;
      approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First-line venetoclax and CD20 antibody containing regimens that are currently being tested&#xD;
      are based on either a fixed duration schedule or on an MRD-based time-limited schedule. The&#xD;
      assumption of these regimens is that, aside from the deep (often uMRD) and often longstanding&#xD;
      remissions, relapsed disease can be retreated with a venetoclax-based regimen. This, however,&#xD;
      has not been formally proven.&#xD;
&#xD;
      In this study, patients who received a first line regimen with either venetoclax and&#xD;
      rituximab (GAIA/CLL13/HOVON 140 trial, [NCT02950051] ) or venetoclax and the second&#xD;
      generation anti-CD20 antibody obinutuzumab (GAIA/CLL13/HOVON 140 trial, and the HOVON139&#xD;
      trial [Netherlands Trial Registry ID number #NTR6043]) and have relapsed with the need for a&#xD;
      subsequent treatment are eligible to enter the study and to receive a combination of&#xD;
      venetoclax with the highly selective BTK inhibitor acalabrutinib. Combination of venetoclax&#xD;
      with acalabrutinib is expected to lead to uMRD, making discontinuation of therapy possible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">December 2032</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>uMRD in BM by flow cytometry after 26 cycles (2 acalabrutinib and 24 AV).</measure>
    <time_frame>26 months</time_frame>
    <description>To evaluate efficacy of acalabrutinib/venetoclax (AV) in terms of undetectable minimal residual disease (uMRD) response in bone marrow (BM) after 26 cycles of treatment in patients with CLL previously treated with venetoclax and anti-CD20 mAb.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>CLL/SLL</condition>
  <arm_group>
    <arm_group_label>Venetoclax/Acalabrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax/Acalabrutinib</intervention_name>
    <description>All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.</description>
    <arm_group_label>Venetoclax/Acalabrutinib</arm_group_label>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented CLL or SLL requiring treatment according to IWCLL criteria (appendix A)&#xD;
             after at least (clinical) partial response as best response after the following&#xD;
             initial study treatment: venetoclax-rituximab in HOVON 140/GAIA or&#xD;
             venetoclax-obinutuzumab in HOVON 139/GIVE or HOVON 140/GAIA;&#xD;
&#xD;
          -  WHO/ECOG performance status 0-3 (appendix C), stage 3 only if attributable to CLL&#xD;
&#xD;
          -  Age at least 18 years;&#xD;
&#xD;
          -  Adequate BM function defined as:&#xD;
&#xD;
               -  Hemoglobin &gt;5 mmol/l or Hb &gt; 8 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;0.75 x 109/L (750/μL), unless directly&#xD;
                  attributable to CLL infiltration of the BM, proven by BM biopsy&#xD;
&#xD;
               -  Platelet count &gt;30 x 109/L (30,000/μL) without transfusion and irrespective&#xD;
                  whether it is attributable to CLL infiltration in the BM;&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) (MDRD) or estimated creatinine clearance&#xD;
             (CrCl ≥ 30ml/min (Cockcroft-Gault appendix E); Please note: in case eGFR or CrCl is&#xD;
             &lt;50ml/min the patient needs to be considered high risk for TLS&#xD;
&#xD;
          -  Adequate liver function as indicated:&#xD;
&#xD;
               -  Serum aspartate transaminase (ASAT) and alanine transaminase (ALAT) ≤ 3.0 x upper&#xD;
                  limit of normal (ULN);&#xD;
&#xD;
               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
                  nonhepatic origin);&#xD;
&#xD;
          -  Prothrombin time (PT)/International normal ratio (INR) &lt;1.5 x ULN and activated&#xD;
             partial thromboplastin time (aPTT) &lt;1.5 x ULN;&#xD;
&#xD;
          -  Negative serological testing for hepatitis B virus (HBV) (Hepatitis B surface antigen&#xD;
             (HBsAg) negative and hepatitis B core antibody (anti-HBc) negative) and hepatitis C&#xD;
             virus (hepatitis C antibody). Subjects who are positive for anti-HBc or hepatitis C&#xD;
             antibody may be included if they have a negative PCR within 6 weeks before enrollment.&#xD;
             Those who are PCR positive will be excluded; Please note: For patients positive for&#xD;
             anti-HBc HBV-DNA PCR has to be repeated every month until 12 months after last dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Patient is able and willing to adhere to the study visit schedule and other protocol&#xD;
             requirements;&#xD;
&#xD;
          -  Patient is capable of giving informed consent;&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior therapy with BTK inhibitor;&#xD;
&#xD;
          -  Prior treatment with venetoclax other than first line;&#xD;
&#xD;
          -  Other therapy with exception of chemo-/immunotherapy which is allowed also after&#xD;
             venetoclax first line relapse;&#xD;
&#xD;
          -  Transformation of CLL (Richter's transformation);&#xD;
&#xD;
          -  Patient with a history of confirmed progressive multifocal leukoencephalopathy (PML);&#xD;
&#xD;
          -  Malignancies other than CLL currently requiring systemic therapy or not treated in&#xD;
             curative intention or showing signs of progression after curative treatment;&#xD;
&#xD;
          -  Known allergy to xanthine oxidase inhibitors and/or rasburicase;&#xD;
&#xD;
          -  History of drug-specific hypersensitivity or anaphylaxis to any study drug (including&#xD;
             active product or excipient components);&#xD;
&#xD;
          -  Active bleeding or history of bleeding diathesis (e.g. hemophilia or von Willebrand&#xD;
             disease);&#xD;
&#xD;
          -  Active fungal, bacterial, and/or viral infection that requires systemic therapy;&#xD;
             Please note: active controlled as well as chronic/recurrent infections are at risk of&#xD;
             reactivation/infection during treatment;&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled: infection,&#xD;
             auto-immune hemolysis, immune thrombocytopenia, diabetes, hypertension,&#xD;
             hyperthyroidism or hypothyroidism etc.);&#xD;
&#xD;
          -  Patient known to be HIV-positive;&#xD;
&#xD;
          -  Patient requiring treatment with a strong cytochrome P450 (CYP) 3A inhibitor/inducer&#xD;
             (see appendix J) or anticoagulant therapy with warfarin or phenoprocoumon or other&#xD;
             vitamin K antagonists; Please note: Patients being treated with DOACs apixaban,&#xD;
             edoxaban or rivaroxaban can be included, but must be properly informed about the&#xD;
             potential risk of bleeding under treatment with acalabrutinib. (see appendix J)&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to registration;&#xD;
&#xD;
          -  Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive&#xD;
             heart failure or symptomatic ischemic heart disease, myocardial infarction within 6&#xD;
             months) (CTCAE grade III-IV, see appendix D);&#xD;
&#xD;
          -  Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D);&#xD;
&#xD;
          -  Severe neurological or psychiatric disease (CTCAE grade III-IV, see appendix D);&#xD;
&#xD;
          -  Patient who has difficulty with or are unable to swallow oral medication, or have&#xD;
             significant gastrointestinal disease that would limit absorption of oral medication;&#xD;
&#xD;
          -  Vaccination with live vaccines within 28 days prior to registration;&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 28 days of registration;&#xD;
&#xD;
          -  Major surgery within 28 days prior to registration;&#xD;
&#xD;
          -  Steroid therapy within 10 days prior to registration, with the exception of inhaled&#xD;
             steroids for asthma, topical steroids, steroids up to 20 mg or dose equivalents of&#xD;
             prednisolone daily to control autoimmune phenomenon's, or replacement/stress&#xD;
             corticosteroids;&#xD;
&#xD;
          -  Pregnant women and nursing mothers;&#xD;
&#xD;
          -  Fertile men or women of childbearing potential unless: (1) surgically sterile or ≥ 2&#xD;
             years after the onset of menopause; (2) willing to use a highly effective&#xD;
             contraceptive method such as oral contraceptives, intrauterine device, sexual&#xD;
             abstinence or combination of male condom with either cap, diaphragm, or sponge with&#xD;
             spermicide (double barrier methods) during study treatment and for 30 days after end&#xD;
             of treatment;&#xD;
&#xD;
          -  Current participation in other clinical trial (other than follow up&#xD;
             HOVON139/HOVON140);&#xD;
&#xD;
          -  Any psychological, familial, sociological and geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Kater</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMC/HOVON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>A. Kater</last_name>
    <phone>+31 20 5665785</phone>
    <email>a.p.kater@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>H. Zanders</last_name>
    <phone>+31 10 7041560</phone>
    <email>w.zanders@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BE-Bruxelles-STLUC</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>BE-Leuven-UZLEUVEN</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DK-Aarhus N-AUH</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Amsterdam-AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Arnhem-RIJNSTATE</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Breda-AMPHIA</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Delft-RDGG</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Den Bosch-JBZ</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Dordrecht-ASZ</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Ede-ZGV</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Eindhoven-MAXIMAMC</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Groningen-UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Leeuwarden-MCL</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Maastricht-MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Nieuwegein-ANTONIUS</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Rotterdam-IKAZIA</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Rotterdam-MAASSTADZIEKENHUIS</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Utrecht-UMCUTRECHT</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.hovon.nl</url>
    <description>Website of the HOVON organisation</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Acalabrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

